Eli Lilly Launched LillyDirect Platform in Australia
The pharmaceutical giant expanded its direct-to-consumer delivery service for the diabetes drug Mounjaro.
Updated on Sept. 30, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical companies to handle direct-to-consumer delivery of prescription medication?
Eli Lilly has officially launched its online platform, LillyDirect, in Australia to provide home delivery for the injectable medication Mounjaro. This expansion follows the platform's initial rollout in the United States in 2024.
Why it matters
The company introduced the service to enhance drug accessibility and convenience for patients managing type 2 diabetes and obesity. However, the direct-to-consumer model has faced significant criticism from medical professionals and pharmacists.
Private patients currently pay up to $700 per month for Mounjaro, though LillyDirect users report savings of up to $50. Eli Lilly also reported a 48 percent increase in quarterly revenue.
The players
Eli Lilly
Eli Lilly is a global pharmaceutical corporation that develops and manufactures treatments for diabetes and obesity.
The details
Through the platform, patients upload an e-script from their doctor, which is then processed and dispensed by an online third-party pharmacist for home delivery. This launch follows Eli Lilly's decision in April 2026 to decline a Pharmaceutical Benefits Scheme listing for the medication.
Timeline
2024: LillyDirect launched in the United States.
April 2026: Eli Lilly declined a Pharmaceutical Benefits Scheme listing.
September 2026: LillyDirect launched in Australia.
Health Landscape
The decision to bypass the Australian Pharmaceutical Benefits Scheme marks a shift in how manufacturers distribute drugs compared to traditional government-subsidized pathways. Eli Lilly explicitly declined a listing under the Pharmaceutical Benefits Scheme, favoring a direct-to-consumer retail model instead.
Patients can now access Mounjaro through an online platform, potentially reducing out-of-pocket costs by up to $50 per month. Users must still obtain an e-script from a physician to utilize the home delivery service.
The takeaway
While direct-to-consumer models offer convenience, patients should verify that online prescription fulfillment aligns with their local medical regulations. Consulting with a primary care provider remains essential to ensure the safe and proper management of chronic conditions.
Further reading
Learn more about the latest developments in Diabetes management and treatment access.
Source note: This article includes information reported by Australian Broadcasting Corporation.
Live Poll
Do you trust pharmaceutical companies to handle direct-to-consumer delivery of prescription medication?
